Drug Trial Radar · NCT04840927
A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants
Last checked: Nov 19, 2026Latest source record: Nov 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Withdrawn
Enrollment
0
Actual
Start
Apr 9, 2021
Primary completion
May 17, 2023
Study completion May 17, 2023
Sponsor
- Lead sponsor
- Eisai LimitedEisai
- Sponsor type
- Industry
- First posted
- Apr 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 30 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The primary purpose of this study is to evaluate the pharmacokinetic (PK) profile of E7386 following oral administration of E7386 enteric coated TR prototype tablet formulations (TR1, TR2 and optional TR3) and to evaluate the relative bioavailability of E7386 TR tablets compared to E7386 IR reference tablet.
Conditions
- Healthy Volunteers
Interventions
E7386Drug
Regimen A: 40 milligram (mg) IR Oral Tablet.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cmax: Maximum Observed Plasma Concentration for E7386Time frame: Day 1: 0-48 hours post-dose
- Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for E7386Time frame: Day 1: 0-48 hours post-dose
- AUC (0-t): Area Under the Concentration-time Curve From Zero (Pre-dose) to Time of Last Quantifiable Concentration for E7386Time frame: Day 1: 0-48 hours post-dose
- AUC (0-inf): Area Under the Concentration-time Curve From Zero (Pre-dose) Extrapolated to Infinite Time for E7386Time frame: Day 1: 0-48 hours post-dose
- T1/2: Terminal Elimination Phase Half-life for E7386Time frame: Day 1: 0-48 hours post-dose
- CL/F: Apparent Total Clearance Following Extravascular Administration for E7386Time frame: Day 1: 0-48 hours post-dose
- Vz/F: Apparent Volume of Distribution at Terminal Phase for E7386Time frame: Day 1: 0-48 hours post-dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Quotient Sciences
Nottingham, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.